Washington’s funding cuts to some HIV-prevention programs in Africa left efforts there floundering, sparking fears that the continent could see hundreds of thousands of additional deaths from AIDS. A global health advocate said a large-scale rollout of the affordable drug could help “bring an end to the HIV epidemic.”
FDA tentatively approves low-cost HIV prevention shot for developing nations
Generic lenacapavir injection available for $40 per person per year in 120 low- and middle-income countries
The U.S. Food and Drug Administration has tentatively approved a generic version of lenacapavir, a twice-a-year injection that helps prevent HIV infection; the move will make the drug available for $40 per person per year in 120 low- and middle-income countries.
The Daily Edition
The front page in your inbox each weekday morning: the lead, the picks, and why each one earned its place.
§
Analysis
Why This Matters
- The low cost of $40 per year could make HIV prevention accessible in poor countries.
- It addresses the gap left by Western funding cuts to African health programs.
- The drug could reduce new HIV infections and save lives.
Background
The FDA's tentative approval marks a step forward for a generic version of the HIV prevention drug lenacapavir. Recent Western aid cuts have undermined prevention efforts in Africa, but this affordable injection could help counter that impact.
What to Watch
- Rollout of the drug in the 120 eligible countries.
- Whether the $40 price point is maintained.
- The response from global health organizations and governments.
Sources
Checked
7 claims in this story checked against 1 source: 7 supported.
Show each claim
- SupportedThe FDA tentatively approved a low-cost HIV-prevention shot for developing nations.Semafor: “The FDA granted tentative approval of a generic lenacapavir, a twice-a-year injection that helps prevent HIV infection. The move will make the drug available for $40 per person a year in 120 low- and middle-income countries”
- SupportedA generic lenacapavir injection will be available for $40 per person per year in 120 low- and middle-income countries.Semafor: “The move will make the drug available for $40 per person a year in 120 low- and middle-income countries”
- SupportedThe FDA tentatively approved a generic version of lenacapavir.Semafor: “The FDA granted tentative approval of a generic lenacapavir”
- SupportedLenacapavir is a twice-a-year injection that helps prevent HIV infection.Semafor: “a twice-a-year injection that helps prevent HIV infection”
- SupportedWashington’s funding cuts to some HIV-prevention programs in Africa left efforts there floundering.Semafor: “Washington’s funding cuts to some HIV-prevention programs in Africa left efforts there floundering”
- SupportedThose cuts sparked fears that Africa could see hundreds of thousands of additional AIDS deaths.Semafor: “sparking fears that the continent could see hundreds of thousands of additional deaths from AIDS”
- SupportedA global health advocate said a large-scale rollout of the affordable drug could help “bring an end to the HIV epidemic.”Semafor: “A large-scale rollout of the affordable drug could help “ bring an end to the HIV epidemic ,” a global health advocate said.”